Otezla was acquired by Amgen for $13.4 billion ... to defend its product by expanding the label of the drug to include mild psoriasis. Last December, it secured FDA approval for the treatment ...

Otezla is currently approved only for moderate-to-severe psoriasis, although Amgen has ongoing trials in milder forms of the disease and analysts have predicted it could become a $2.5 billion product.

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

RARELY SEE THOSE CLOUDS IN THE SUNRISE. PEEKING THROUGH TEMPERATURES A LITTLE COOLER THIS MORNING, ESPECIALLY CONSIDERING HOW MILD THESE LAST FEW MORNINGS HAVE BEEN. 49 BLAIR 50 NOW COUNCIL BLUFFS ...

Nail problems affect nearly 10% of adults, with fungal infections outnumbering psoriasis cases by almost three to one. This prevalence disparity leads many people to automatically assume any nail ...

Currently, they can treat shingles, mild psoriasis, urinary tract infections and provide medications such as oral contraceptives. Loading Victoria has 29 urgent-care clinics which the Allan ...

If the drug is used properly by GPs, I expect to see referrals to dermatologists drop by about 50 per cent. 'I expect Dovobet to work on about 80 per cent of people with mild psoriasis.' ...